Disseminated cryptococcosis in a patient with COVID-19

Criptococosis diseminada en paciente positivo para COVID-19

Here, we report a case of a 59-year-old patient with a 2-day history of moderate intensity (7/10) holocranial headache, unquantified febrile peaks, grade III dyspnea, adynamia, hyporexia, ageusia and nonproductive cough admitted to the emergency department. He referred close contact to a sister with confirmed COVID-19. His COVID-19 antigen test results were positive. Severe acute respiratory syndrome (SARS-CoV-2) associated with Cryptococcus neoformans infection was confirmed. The use of systemic corticosteroid therapy leads to immunocompromise and predisposes the patient to common and opportunistic infections such as Cryptococcus neoformans and Cryptococcus gatiii infection. In this case COVID-19 infection and the development of SARS-CoV-2 was the etiology of the Cryptococcus fungal infection.

1. Accini Mendoza JL, Nieto Estrada VH, Beltrán López N, Ramos Bolaños E. Declaración de consenso en medicina crítica para la atención multidisciplinaria del paciente con sospecha o confirmación diagnóstica de COVID-19. Colombia: Asociación Colombiana de Medicina Crítica y Cuidado Intensivo AMCI; 2020. p. 7.
2. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi: 10.1016/S0140-6736(20)30183-5
3. Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science. 2020;368(6490):473–4. doi: 10.1126/science.abb8925
4. Goyal P. Clinical Characteristics of Covid-19 in New York City. N Engl J Med 2020; 382:2372-2374. doi: 10.1056/NEJMc2010419
5. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected with SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020;323(16):1574-1581. doi: 10.1001/jama.2020.5394
6. Maes M, Higginson E, Pereira-Dias J, Curran MD, Parmar S, Khokhar F, et al. Ventilator-associated pneumonia in critically ill patients with COVID-19. Crit Care. Crit Care. 2021 Jan 11;25(1):25. doi: 10.1186/s13054-021-03460-5
7. RECOVERY Collaborative Group, Horby P, Shen Lim W, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021;384(8):693-704. doi: 10.1056/NEJMoa2021436
8. Yang Z, Hospital JC, Hu Q, Hospital JC, Huang F, Hosiptal JC, et al. The Prognostic Value of the SOFA Score in Patients with COVID-19 : A Retrospective , Observational Study. Res Sq. 2020. doi: 10.21203/rs.3.rs-67639/v1
9. Mercier T, Dunbar A, Veldhuizen V, Holtappels M, Schauwvlieghe A, Maertens J, et al. Point of care aspergillus testing in intensive care patients. Crit Care. 2020;24:642. doi: 10.1186/s13054-020-03367-7
10. Koehler P, Cornely OA, Böttiger BW, Dusse F, Eichenauer DA, Fuchs F, et al. COVID-19 associated pulmonary aspergillosis. Mycoses. 2020;63(6):528–34. doi: 10.1111/myc.13096
11. Castañeda E, Lizarazo J. Protocolo de estudio y manejo de los pacientes con criptococosis A protocol for the study and management of patients with cryptococcosis Infectio Asociación Colombiana de Infectología. Infectio. 2012;16(3):123–5. doi: 10.1016/S0123-9392(12)70038-3
12. Alanio A, Dellière S, Fodil S, Bretagne S, Mégarbane B. Prevalence of putative invasive pulmonary aspergillosis in critically ill patients with COVID-19. Lancet Respir Med. 2020;8(6):e48–9. doi: 10.1016/S2213-2600(20)30237-X